Megan completed her PhD in 2018 at the University of Liverpool under the supervision of Professor Andrew Owen and Dr Marco Siccardi. Her PhD combined pharmacogenetic analysis and in vitro studies to investigate the role of patient genetics on drug-drug interactions and drug toxicity in patients receiving HIV antiretroviral drugs. During this time, Megan worked with multiple international collaborators and provided training in pharmacogenetics wet lab techniques and at IDI Makerere University in Uganda. After her PhD Megan took up a postdoctoral position in Professor Andrew Owens group conducting preclinical investigations of long acting antiretroviral therapies. Megan’s research is focused on emerging approaches in the field, such as biodegradable implants and investigating new methodologies not currently used in the long acting drug development process. In 2020, Megan was awarded a Wellcome Trust funded institutional strategic support fund to study the suitability of non-mammalian organisms for use within the preclinical drug development pipeline. She is also interested more broadly in infection pharmacology research that affects women’s health and the ways in which long acting and multipurpose technologies can provide solutions to the specific challenges faced by women. During the COVID19 pandemic Megan has been involved in drug re-purposing studies to investigate potential therapeutics for use against SARS-CoV-2.
Prizes or Honours
- Young Investigator Scholarship (Conference on Retroviruses and Opportunistic Infections, 2018)
- Young Investigator Scholarship (Conference on Retroviruses and Opportunistic Infections, 2017)
- Young Investigator Scholarship (Conference on Retroviruses and Opportunistic Infections, 2016)